| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/02/2009 | WO2009039988A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 04/02/2009 | WO2009039987A1 Use of peptide thr-thr-ser-gln-val-arg-pro-arg as a therapeutic agent |
| 04/02/2009 | WO2009039986A2 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 04/02/2009 | WO2009039985A2 Therapeutic uses of urocortin ii |
| 04/02/2009 | WO2009039984A2 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 04/02/2009 | WO2009039983A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039982A2 Use of gip alone or in combination with dynorphin b as a therapeutic agent |
| 04/02/2009 | WO2009039981A2 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039980A2 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039979A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | WO2009039978A2 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 04/02/2009 | WO2009039977A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection |
| 04/02/2009 | WO2009039976A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039974A2 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039973A2 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039971A2 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents |
| 04/02/2009 | WO2009039970A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | WO2009039969A2 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 04/02/2009 | WO2009039968A2 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039966A2 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039964A2 Use of glucagon-like peptide as a therapeutic agent |
| 04/02/2009 | WO2009039963A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | WO2009039960A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009039957A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| 04/02/2009 | WO2009039943A1 (carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament |
| 04/02/2009 | WO2009039942A1 (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament |
| 04/02/2009 | WO2009039635A1 Methods of modulating neurotrophin-mediated activity |
| 04/02/2009 | WO2009023269A3 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases |
| 04/02/2009 | WO2009018333A3 Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| 04/02/2009 | WO2009016227A3 Novel compounds |
| 04/02/2009 | WO2009012425A3 Compositions including leukotriene antagonists and nsaids and methods of using the same |
| 04/02/2009 | WO2009010299A8 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 04/02/2009 | WO2009007110A3 Combination of benzyl-4,5-dihydro-1h-imidazole derivative and an opiod recptor ligand |
| 04/02/2009 | WO2008156832A3 Renin inhibitors |
| 04/02/2009 | WO2008155357A3 Use of dopamine stabilizers |
| 04/02/2009 | WO2008141097A9 Stereoisomers propofol therapeutic compounds |
| 04/02/2009 | WO2008132464A3 Mek5 and related proteins as biomarkers of neurodegenerative diseases |
| 04/02/2009 | WO2007011820A3 Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 04/02/2009 | US20090088470 Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
| 04/02/2009 | US20090088469 Method for the preparation of citalopram |
| 04/02/2009 | US20090088457 Primary Amines as Renin Inhibitors |
| 04/02/2009 | US20090088455 Chronic, Bolus Adminstration Of D-Threo Methylphenidate |
| 04/02/2009 | US20090088449 4-acylaminopyridine derivative mediated neurogenesis |
| 04/02/2009 | US20090088448 Rapamycin Derivatives and the Uses Thereof in the Treatment of Neurological Disorders |
| 04/02/2009 | US20090088437 nicotinic receptor agonists such as 3-{[(1S,4S)-5-Methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl}-1,2-benzisothiazole, used for the treatment of brain disorders |
| 04/02/2009 | US20090088429 Isoquinoline Derivatives |
| 04/02/2009 | US20090088417 Vanilloid receptor antagonist for prevention and treatment of drug dependence and addiction |
| 04/02/2009 | US20090088406 N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors |
| 04/02/2009 | US20090088404 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| 04/02/2009 | US20090088394 Methods and compositions for therapeutic treatment |
| 04/02/2009 | US20090088389 Novel x-conotoxin peptides (-ii) |
| 04/02/2009 | US20090088383 Gh secretagogues and uses thereof |
| 04/02/2009 | US20090088368 Compositions comprising them as ppar modulators |
| 04/02/2009 | US20090087490 Extended release formulation and method of treating adrenergic dysregulation |
| 04/02/2009 | US20090087487 Paliperidone sustained release formulation |
| 04/02/2009 | US20090087481 Using mixture comprising colony stimulating factor, interleukin-5 and/or a mimetic as therapeutic tool in treatment of nervous system disorders |
| 04/02/2009 | US20090087474 Therapeutic use of growth factors,nsg29 and nsg31 |
| 04/02/2009 | US20090087458 Activatable recombinant neurotoxins |
| 04/02/2009 | US20090087436 Compositions and methods for treating diseases |
| 04/02/2009 | US20090087423 Novel protein complex and use thereof |
| 04/02/2009 | US20090087417 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands |
| 04/02/2009 | US20090087376 Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease |
| 04/02/2009 | DE102007045476A1 Neue heteroarylsubstituierte Acetonderivate, geeignet zur Hemmung der Phospholipase A2 New heteroaryl acetone derivatives useful for inhibiting phospholipase A2 |
| 04/02/2009 | CA2700841A1 Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| 04/02/2009 | CA2700835A1 Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
| 04/02/2009 | CA2700536A1 Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| 04/02/2009 | CA2700088A1 Quinolone derivative |
| 04/02/2009 | CA2700028A1 (carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament |
| 04/02/2009 | CA2700025A1 (cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament |
| 04/02/2009 | CA2699787A1 (3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| 04/02/2009 | CA2699697A1 Quinoline derivatives as 5ht5a receptor antagonists |
| 04/02/2009 | CA2699244A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | CA2699241A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699177A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699170A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699154A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699153A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699101A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699100A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699077A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699073A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699069A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699068A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699065A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699055A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699054A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699052A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699049A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699047A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699039A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | CA2699035A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | CA2699000A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-arg-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | CA2698775A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698772A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698768A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698764A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698762A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | CA2698751A1 Use of a peptide as a therapeutic agent |